Laboratory studies have shown that RAD001 can prevent cells from multiplying. Consequently,
the study drug is being tested in medical conditions in which excessive cell multiplication
(as in cancer) needs to be stopped. The main purpose of this research study is to find the
highest dose of RAD001 that can be given safely (without causing severe side effects) and to
learn the effects (good or bad) RAD001 has on participants with liver cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Novartis